Adam’s Take

Insights and opinions from senior biotech writer Adam Feuerstein

JPM 2020 Lombard St
Adam's Take

The truth about JPM: Less is more

By Adam Feuerstein

JPM 2020 Lombard St
Adam's Take

All talk, no M&A makes for a down JPM Day

By Adam Feuerstein

Adam's Take

Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA

By Adam Feuerstein

Adam's Take

Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts

By Adam Feuerstein

2010- 2019 Medicine
Biotech

STAT’s guide to the most important, beneficial drugs approved in the past decade

By Adam Feuerstein and Matthew Herper

Good/Bad CEO 2017
Adam's Take

Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list

By Adam Feuerstein

BAD CEOS
Adam's Take

And now, your nominees for worst biopharma CEO of 2019. Let the voting begin!

By Adam Feuerstein

Good CEOs
Adam's Take

Here are the nominees for best biopharma CEO of 2019. Vote for your favorite!

By Adam Feuerstein

Adam's Take

The good, the bad, and the really, really ugly behind Sarepta’s drug approval

By Adam Feuerstein

Adam's Take

Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock

By Adam Feuerstein

Adam's Take

Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval

By Adam Feuerstein

Adam's Take

A cancer company has misled investors repeatedly about its drug. It’s time for some truth-telling

By Adam Feuerstein

Adam's Take

The bearish view of Acadia Pharma’s antipsychotic drug takes a hit with positive trial results

By Adam Feuerstein

Vivek Ramaswamy
Adam's Take

Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share

By Adam Feuerstein

Adam's Take

Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person

By Adam Feuerstein

Adam's Take

FDA’s Sarepta rejection is rooted in the past, and will weigh on its future

By Adam Feuerstein

Adam's Take

This troubled biotech needed cash, so it turned to a predatory lender: its own CEO

By Adam Feuerstein

Adam's Take

Sarepta’s bad week raised questions about its gene therapy program. Here are some answers

By Adam Feuerstein

Adam's Take

Show us the data: Bluebird raises questions by sitting on results of CAR-T drug critical to its future

By Adam Feuerstein

Adam's Take

With another trial failure, it may be time to revoke the approval of Acadia Pharma’s anti-psychosis drug

By Adam Feuerstein

Adam's Take

The FDA erred in approving new women’s libido drug; don’t reward Palatin Technologies

By Adam Feuerstein

Adam's Take

Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk

By Adam Feuerstein

Vascepa pill handout
Adam's Take

Sales of Amarin’s heart drug are surging, but the stock not so much. Here’s why

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: ResTORbio, Trovagene, Atossa Genetics

By Adam Feuerstein

Biotech

Biogen-Eisai partnership may be hitting a rough patch following Alzheimer’s drug blowup

By Adam Feuerstein

Adam's Take

Cowen polled investors and doctors on the outlook for new biotech drugs. Here’s what they said

By Adam Feuerstein

Adam's Take

Taking the measure of small-cap biotech: Bio-Path Holdings, CytoDyn

By Adam Feuerstein

Celgene breakup mix tape
Adam's Take

Suddenly, the Bristol-Celgene deal is looking shaky. What might be next for Celgene?

By Adam Feuerstein

Afrezza
Adam's Take

Wait … what? MannKind posts best-ever quarter of inhaled insulin product sales

By Adam Feuerstein

Your daily dose of news in health and medicine

Privacy Policy